Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.

被引：21

作者：

Burris, Howard A.

Callahan, Margaret K.

Tolcher, Anthony W.

Kummar, Shivaani

Falchook, Gerald Steven

Pachynski, Russell Kent

Tykodi, Scott S.

Gibney, Geoffrey Thomas

Seiwert, Tanguy Y.

Gainor, Justin F.

LoRusso, Patricia

Hilbert, James

Apgar, Josh F.

Hua, Fei

Burke, John M.

Lazard, Manny

Clancy, Myles

Ding, Baoyu

Trehu, Elizabeth G.

Yap, Timothy Anthony

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] START, San Antonio, TX USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Sarah Cannon Res Inst HealthONE, Denver, CO USA

[6] Washington Univ, Sch Med St Louis, St Louis, MO USA

[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA 98195 USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

[11] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[12] Appl Biomath, Lincoln, MA USA

[13] Jounce Therapeut, Cambridge, MA USA

[14] MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.3033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3033

引用

页数：6